CIBC Asset Management
TXMD icon

CIBC Asset Management’s TherapeuticsMD TXMD Stock Holding History

CIBC Asset Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-246
Closed -$15K – 1497
2021
Q2 		$15K Hold
246
– – ﹤0.01% 1361
2021
Q1 		$16K Buy
246
+29
+13% +$2.27K ﹤0.01% 1328
2020
Q4 		$13K Hold
217
– – ﹤0.01% 1237
2020
Q3 		$17K Buy
217
+5
+2% +$399 ﹤0.01% 1113
2020
Q2 		$13K Hold
212
– – ﹤0.01% 1082
2020
Q1 		$11K Hold
212
– – ﹤0.01% 1008
2019
Q4 		$26K Buy
+212
New +$30.5K ﹤0.01% 1179

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CIBC Asset Management's TXMD Position: Q3 2021 in Review

CIBC Asset Management sold out of TherapeuticsMD (TXMD) in Q3 2021, closing a stake of 246 shares — an estimated $15K sold.

CIBC Asset Management first reported a position in TXMD in Q4 2019 and held it in 7 quarters. The position peaked at $26K in Q4 2019. 149 funds tracked by Wall St. Rank hold TXMD as of Q3 2021.

  • CIBC Asset Management reported no remaining TherapeuticsMD position as of Q3 2021 after selling out during the quarter.
  • CIBC Asset Management sold 246 TherapeuticsMD shares in Q3 2021, an estimated $15K.
  • CIBC Asset Management first reported a position in TherapeuticsMD in Q4 2019 and held it in 7 quarters.
  • CIBC Asset Management's TherapeuticsMD position peaked at $26K in Q4 2019.
  • 149 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2021.

Based on CIBC Asset Management's 13F filing for Q3 2021, filed 9 Nov 2021.